文献速递慢性肾脏病血液净化与透析

vadadustat治疗慢性肾脏病贫血的全球3期项目:INNO2VATE试验中透析依赖患者的基本特征

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

INNO2VATE项目包含两项3期开放标签、申办方盲、活性对照试验,分别纳入新近开始透析且ESA暴露有限(incident DD-CKD)和维持透析且接受ESA治疗(prevalent DD-CKD)的成人贫血患者,评估vadadustat对比达依泊汀α的安全性和有效性。两项试验分别随机369例和3554例患者,人口学和基线特征相似,且与DD-CKD典型人群相当。

要点

  • vadadustat是一种口服HIF-PHI,可刺激内源性促红细胞生成素生成。
  • INNO2VATE项目包括incident和prevalent DD-CKD两项3期试验。
  • 主要安全性终点为首次主要不良心血管事件时间,主要疗效终点为血红蛋白变化。

核心结论

  • INNO2VATE试验将为vadadustat在多样化DD-CKD人群中管理贫血的安全性和有效性提供重要信息。
  • 入组患者的人口学和基线特征提示研究结果可代表大部分DD-CKD人群。

研究设计与样本

  • 两项3期、开放标签、申办方盲、活性对照试验,纳入DD-CKD贫血成人患者。
  • incident DD-CKD试验纳入近期开始透析且ESA暴露有限的患者,prevalent DD-CKD试验纳入接受维持透析且ESA治疗的患者。
  • 研究期包括纠正/转换期(第0-23周)、维持期(第24-52周)、长期治疗期(第53周至治疗结束)和安全性随访。
  • incident试验随机369例,prevalent试验随机3554例。

主要发现

  • 两项试验中患者人口学和基线特征相似,且与DD-CKD典型特征相当。
  • 主要安全性终点为首次主要不良心血管事件时间,主要疗效终点为血红蛋白从基线至第24-36周的变化。

关键数值与推荐

  • 主要安全性终点:首次主要不良心血管事件时间。
  • 主要疗效终点:血红蛋白从基线至第24-36周的变化。

临床怎么用

  • 该研究设计为评估vadadustat对比达依泊汀α在DD-CKD贫血患者中的安全性和有效性提供了框架。
  • 入组人群的代表性提示结果可能适用于广泛的DD-CKD患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are currently the mainstay of treatment for anaemia of chronic kidney disease (CKD). Vadadustat is an investigational oral hypoxia-inducible factor prolyl-hydroxylase inhibitor that stimulates endogenous erythropoietin formation. The INNO2VATE programme comprises two studies designed to evaluate the safety and efficacy of vadadustat versus the ESA darbepoetin alfa in ameliorating anaemia in patients with dialysis-dependent CKD (DD-CKD). Here we describe the trial design along with patient demographics and baseline characteristics. METHODS: Two Phase 3, open-label, sponsor-blind, active-controlled trials enrolled adults with anaemia of CKD who recently initiated dialysis and had limited ESA exposure (incident DD-CKD trial) or were receiving maintenance dialysis with ESA treatment (prevalent DD-CKD trial). Study periods include correction/conversion (Weeks 0-23), maintenance (Weeks 24-52), long-term treatment (Weeks 53 to end of treatment) and safety follow-up. The primary safety endpoint is the time to the first major adverse cardiovascular event and the primary efficacy endpoint is the change in haemoglobin (baseline to Weeks 24-36). RESULTS: A total of 369 and 3554 patients were randomized in the incident DD-CKD and prevalent DD-CKD trials, respectively. Demographics and baseline characteristics were similar among patients in both trials and comparable to those typically observed in DD-CKD. CONCLUSIONS: The two INNO2VATE trials will provide important information on the safety and efficacy of a novel approach for anaemia management in a diverse DD-CKD population. Demographics and baseline characteristics of enrolled patients suggest that study results will be representative for a large proportion of the DD-CKD population.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Eckardt KU, Agarwal R, Farag YM, et al. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant. 2021. PMID: 33188693. doi:10.1093/ndt/gfaa204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。